Edwards Lifesciences CorporationEWNYSE
Loading
Cash Generation ExpandingExpanding
Percentile Rank93
3Y CAGR+11.9%
5Y CAGR+15.6%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
+11.9%/yr
vs +8.6%/yr prior
5Y CAGR
+15.6%/yr
Recent deceleration
Acceleration
+3.3pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $1.33B | +360.5% |
| 2024 | $289.90M | -53.9% |
| 2023 | $629.50M | -34.0% |
| 2022 | $953.40M | -32.0% |
| 2021 | $1.40B | +116.7% |
| 2020 | $647.00M | -28.2% |
| 2019 | $901.00M | +31.5% |
| 2018 | $685.10M | -17.0% |
| 2017 | $825.20M | +69.4% |
| 2016 | $487.00M | - |